‘No clear efficacy benefit’ to combining bezlotoxumab with FMT in IBD, recurrent C. diff
PHILADELPHIA — Bezlotoxumab in combination with fecal microbiota transplantation did not further reduce recurrence of Clostridioides difficile infection in patients with inflammatory bowel disease, according to data presented here. “This was the first clinical trial to assess the clinical effect of FMT in combination with bezlotoxumab in patients with IBD and recurrent C. diff,”